A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors

Autor: Alexander Drilon, Martijn P. Lolkema, Hui K Gan, Robert C. Gagnon, Gopinath Ganji, Carla L.M. Van Herpen, Ignacio Garrido-Laguna, Bruce A. Hug, Jason D. Lickliter, Robin O'Connor-Semmes, Jan H.M. Schellens, Catherine E. Ellis, Christopher Matheny, Michael Millward, Mathilde Jalving, Lihua Tang

Publikováno v: The Oncologist, 26(10), e1844-e1853. ALPHAMED PRESS
The Oncologist
Oncologist, 26, 10, pp. e1844-e1853
Oncologist, 26, e1844-e1853

Background GSK2849330, an anti‐HER3 monoclonal antibody that blocks HER3/Neuregulin 1 (NRG1) signaling in cancer cells, is engineered for enhanced antibody‐dependent cellular cytotoxicity and complement‐dependent cytotoxicity. This phase I, fir

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca765b079fda30d6838b7dbd1c38708d
https://hdl.handle.net/2066/244559

Abdominal Injury-Football

Autor: Catherine E. Ellis, Michael A. Seifert

Publikováno v: Medicine & Science in Sports & Exercise. 54:10-10

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b408b9564ad6eb1764f6ba67f5e997d7
https://doi.org/10.1249/01.mss.0000875176.84180.8d

Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab)

Autor: Wendy R. Parulekar, Rocco J. Crescnzo, Samuel Aparicio, Kim Leitzel, Lois E. Shepherd, Jessica Huang, Dora Nomikos, Suhail M. Ali, Judith Anne W. Chapman, Catherine E. Ellis, Walter P. Carney, Diep Ho, Allan Lipton, Shakeel Virk, Liting Zhu, Karen A. Gelmon

Publikováno v: Breast Cancer Research and Treatment. 164:571-580

The lapatinib–taxane combination led to shorter PFS than trastuzumab–taxane in HER2+ metastatic breast cancer. We investigated the prognostic and predictive effects of pretreatment serum HER2, CAIX, and TIMP-1. MA.31 accrued 652 patients; 537 (82

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86d32142c4cfb8a1f51710248b710d84
https://doi.org/10.1007/s10549-017-4273-x

Inducible T-cell co-stimulatory (ICOS) receptor agonist, feladilimab (fela), alone and in combination (combo) with pembrolizumab (P): Results from INDUCE-1 urothelial carcinoma (UC) expansion cohorts (ECs)

Autor: Catherine E. Ellis, Michael Chisamore, Eric Angevin, Marc S. Ballas, Erminia Massarelli, Debra Rogan, Victor Moreno, Hui K Gan, Axel Hoos, Maria Vieito, Antoine Italiano, Riccardo Danielli, Arjun Vasant Balar, Courtney Henry, Frans L. Opdam, Xiao Ji, Francesco Ricci

Publikováno v: Journal of Clinical Oncology. 39:4519-4519

4519 Background: INDUCE-1 is a first-in-human trial evaluating fela, an IgG4 ICOS agonist non-T-cell depleting mAb, as monotherapy (mono) and in combo with P. ECs include tumor types, such as UC, with high ICOS expression and immunotherapy-favorable

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::888bec756ccc63991f7a91a67f9b0185
https://doi.org/10.1200/jco.2021.39.15_suppl.4519

Abstract P3-07-08: Quantitative HER family proteins assessment as prognostic and predictive biomarkers in the EGF30008 clinical trial

Autor: Robert C. Gagnon, Fabiola Cecchi, S.R.D. Johnston, Sheeno Thyparambil, M Vilaro, Michael F. Press, Patricia Galván, Aleix Prat, Catherine E. Ellis, W-L Liao, Adele Blackler, José Antonio Jiménez, Todd Hembrough, P. Nuciforo

Publikováno v: Cancer Research. 76:P3-07

Background Combined targeted strategy with letrozole (Le) and lapatinib (La) improves progression-free survival (PFS) in patients with metastatic breast cancer (MBC) co-expressing hormone receptor-positive (HR+) and HER2+ but not in HR+/HER2-negative

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bc290cf36d5750ba18eb797f21412b8c
https://doi.org/10.1158/1538-7445.sabcs15-p3-07-08